Literature DB >> 25182655

Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.

Kim Vanstraelen1, Joost Wauters2, Ine Vercammen3, Henriette de Loor4, Johan Maertens5, Katrien Lagrou6, Pieter Annaert7, Isabel Spriet3.   

Abstract

Setting the adequate dose for voriconazole is challenging due to its variable pharmacokinetics. We investigated the impact of hypoalbuminemia (<35 g/liter) on voriconazole pharmacokinetics in adult intensive care unit (ICU) patients treated with voriconazole (20 samples in 13 patients) as well as in plasma samples from ICU patients that had been spiked with voriconazole at concentrations of 1.5 mg/liter, 2.9 mg/liter, and 9.0 mg/liter (66 samples from 22 patients). Plasma albumin concentrations ranged from 13.8 to 38.7 g/liter. Total voriconazole concentrations in adult ICU patients treated with voriconazole ranged from 0.5 to 8.7 mg/liter. Unbound and bound voriconazole concentrations were separated using high-throughput equilibrium dialysis followed by liquid chromatography-tandem mass spectrometry (LC-MSMS). Multivariate analysis revealed a positive relationship between voriconazole plasma protein binding and plasma albumin concentrations (P < 0.001), indicating higher unbound voriconazole concentrations with decreasing albumin concentrations. The correlation is more pronounced in the presence of elevated bilirubin concentrations (P = 0.05). We therefore propose to adjust the measured total voriconazole concentrations in patients with abnormal plasma albumin and total serum bilirubin plasma concentrations who show adverse events potentially related to voriconazole via a formula that we developed. Assuming 50% protein binding on average and an upper limit of 5.5 mg/liter for total voriconazole concentrations, the upper limit for unbound voriconazole concentrations is 2.75 mg/liter. Alterations in voriconazole unbound concentrations caused by hypoalbuminemia and/or elevated bilirubin plasma concentrations cannot be countered immediately, due to the adult saturated hepatic metabolism. Consequently, increased unbound voriconazole concentrations can possibly cause adverse events, even when total voriconazole concentrations are within the reference range.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25182655      PMCID: PMC4249353          DOI: 10.1128/AAC.03641-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  66 in total

1.  High-throughput screening of protein binding by equilibrium dialysis combined with liquid chromatography and mass spectrometry.

Authors:  Hong Wan; Mikael Rehngren
Journal:  J Chromatogr A       Date:  2005-11-02       Impact factor: 4.759

2.  Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients.

Authors:  I Mohammedi; M A Piens; C Padoin; D Robert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-05       Impact factor: 3.267

3.  Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis.

Authors:  Stefan Weiler; Heinz Zoller; Ivo Graziadei; Wolfgang Vogel; Rosa Bellmann-Weiler; Michael Joannidis; Romuald Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2007-07-02       Impact factor: 5.191

4.  Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.

Authors:  S Trifilio; R Ortiz; G Pennick; A Verma; J Pi; V Stosor; T Zembower; J Mehta
Journal:  Bone Marrow Transplant       Date:  2005-03       Impact factor: 5.483

5.  A theoretical method for normalizing total serum valproic acid concentration in hypoalbuminemic patients.

Authors:  Jesús Hermida; J Carlos Tutor
Journal:  J Pharmacol Sci       Date:  2005-04       Impact factor: 3.337

6.  Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia.

Authors:  G D Anderson; C Pak; K W Doane; K G Griffy; N R Temkin; A J Wilensky; H R Winn
Journal:  Ann Pharmacother       Date:  1997-03       Impact factor: 3.154

7.  [Severe phenytoin intoxication in patients with hypoalbuminaemia].

Authors:  E M Kemper; H J M van Kan; P Speelman; K de Gans; J H Beijnen; J H M Schellens
Journal:  Ned Tijdschr Geneeskd       Date:  2007-01-13

8.  Phenytoin intoxication in critically ill patients.

Authors:  Gert De Schoenmakere; Jan De Waele; Wim Terryn; Mieke Deweweire; Alain Verstraete; Eric Hoste; Sylvie Rottey; Norbert Lameire; Francis Colardyn
Journal:  Am J Kidney Dis       Date:  2005-01       Impact factor: 8.860

9.  Estimating phenytoin concentrations by the Sheiner-Tozer method in adults with pronounced hypoalbuminemia.

Authors:  W E Dager; J F Inciardi; T L Howe
Journal:  Ann Pharmacother       Date:  1995 Jul-Aug       Impact factor: 3.154

Review 10.  Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

View more
  10 in total

1.  In vitro study of the variable effects of proton pump inhibitors on voriconazole.

Authors:  Krista L Niece; Natalie K Boyd; Kevin S Akers
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

2.  Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole.

Authors:  Kim Vanstraelen; Johan Maertens; Patrick Augustijns; Katrien Lagrou; Henriette de Loor; Raf Mols; Pieter Annaert; Anne Malfroot; Isabel Spriet
Journal:  Clin Pharmacokinet       Date:  2015-11       Impact factor: 6.447

3.  Factors impacting unbound vancomycin concentrations in different patient populations.

Authors:  Matthijs Oyaert; Isabel Spriet; Karel Allegaert; Anne Smits; Kim Vanstraelen; Nele Peersman; Joost Wauters; Jan Verhaegen; Pieter Vermeersch; Steven Pauwels
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

4.  Determination of Voriconazole Plasma Concentration by HPLC Technique and Evaluating Its Association with Clinical Outcome and Adverse Effects in Patients with Invasive Aspergillosis.

Authors:  Sahar Yousefian; Farzaneh Dastan; Majid Marjani; Payam Tabarsi; Saghar Barati; Nahid Shahsavari; Farzad Kobarfard
Journal:  Can J Infect Dis Med Microbiol       Date:  2021-04-12       Impact factor: 2.471

5.  Clinical Features, Diagnostic Test Performance, and Prognosis in Different Subtypes of Chronic Pulmonary Aspergillosis.

Authors:  Huanhuan Zhong; Yaru Wang; Yu Gu; Yueyan Ni; Yu Wang; Kunlu Shen; Yi Shi; Xin Su
Journal:  Front Med (Lausanne)       Date:  2022-02-11

6.  Inflammation Affects Liver Function and the Metabolism of Voriconazole to Voriconazole-N-Oxide in Adult and Elderly Patients.

Authors:  Zaiming Liang; Mingjie Yu; Zhirui Liu; Fang Liu; Changsheng Jia; Lirong Xiong; Qing Dai; Shiwei Qin; Lin Cheng; Fengjun Sun
Journal:  Front Pharmacol       Date:  2022-04-06       Impact factor: 5.988

7.  Prediction of Unbound Vancomycin Levels in Intensive Care Unit and Nonintensive Care Unit Patients: Total Bilirubin May Play an Important Role.

Authors:  Xiao Li; Wen Xu; Ran Li; Qie Guo; Xiangpeng Li; Jialin Sun; Shuhong Sun; Jing Li
Journal:  Infect Drug Resist       Date:  2021-07-02       Impact factor: 4.003

8.  New insights into the clinical characteristics and prognostic factors of pulmonary fungal infections from a retrospective study in Southwestern China.

Authors:  Li Peng; Zhiping Xu; Zhenyu Huo; Rui Long; Liang Ma
Journal:  Infect Drug Resist       Date:  2018-03-05       Impact factor: 4.003

9.  Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients.

Authors:  Yi-Chang Zhao; Xiao-Bin Lin; Bi-Kui Zhang; Yi-Wen Xiao; Ping Xu; Feng Wang; Da-Xiong Xiang; Xu-Biao Xie; Feng-Hua Peng; Miao Yan
Journal:  Clin Transl Sci       Date:  2020-11-30       Impact factor: 4.689

Review 10.  Recent Advances in Therapeutic Drug Monitoring of Voriconazole, Mycophenolic Acid, and Vancomycin: A Literature Review of Pediatric Studies.

Authors:  Matylda Resztak; Joanna Sobiak; Andrzej Czyrski
Journal:  Pharmaceutics       Date:  2021-11-23       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.